Cromolyn sodium salt (Disodium cromoglycate) - ≥95% purity mast cell stabilizer soluble in water for anti-allergy medication

Cromolyn sodium salt (disodium cromoglycate) is a bis-chromone derivative that functions as a reference mast cell stabilizer by inhibiting calcium influx and degranulation in sensitized mast cells

Description of Cromolyn sodium salt (disodium cromoglycate) CAS:15826-37-6

Cromolyn sodium salt (disodium cromoglycate; CAS 15826-37-6) is a bis-chromone derivative that functions as a reference mast cell stabilizer by inhibiting calcium influx and degranulation in sensitized mast cells. The ≥95% purity grade (Sigma C0399) is a widely cited research formulation that provides aqueous solubility of 100 mg/mL—approximately five-fold higher than structurally related mast cell stabilizers nedocromil sodium and lodoxamide tromethamine—rendering it particularly suitable for in vitro perfusion assays, intraperitoneal administration, and ex vivo tissue bath studies where high local drug concentrations are required.

Applications of Cromolyn sodium salt (disodium cromoglycate) CAS:15826-37-6

Mast Cell Signaling Studies Requiring Pathway-Selective Pharmacology Without H1 Receptor Confounding

In experiments designed to dissect IgE-dependent mast cell degranulation pathways (e.g., calcium flux imaging, mediator release profiling, or signaling kinase activation assays), cromolyn sodium salt ≥95% provides a pure mast cell stabilizer tool devoid of histamine H1 receptor binding (Ki > 10 µM vs. olopatadine Ki = 36 nM) [1]. This pharmacological profile ensures that observed effects on downstream signaling are attributable to mast cell stabilization rather than blockade of autocrine histamine feedback. The compound's 100 mg/mL aqueous solubility permits formulation of high-concentration stock solutions without DMSO, eliminating solvent-induced mast cell activation artifacts. Protocol precedent exists for Sigma C0399 in MRGPRX antagonist screening assays, confirming compatibility with contemporary receptor pharmacology platforms .

In Vivo Mast Cell Stabilization in Rodent Disease Models Requiring High-Dose Intraperitoneal Administration

For rodent studies requiring sustained systemic mast cell stabilization (e.g., polycystic kidney disease, ischemia–reperfusion injury, or hypoxia-induced vascular remodeling), cromolyn sodium salt ≥95% enables preparation of concentrated aqueous dosing solutions (40 mg/kg in ≤0.4 mL PBS i.p.) without viscosity or precipitation issues that limit nedocromil sodium (20 mg/mL solubility ceiling) or lodoxamide tromethamine (18 mg/mL) [1]. The PCK rat study by Jiang et al. (2018) demonstrated that cromolyn sodium produced significant renal cyst reduction (P < 0.05 vs. control), an effect not replicated by ketotifen, establishing organ-specific efficacy in this model . In the hypoxia model of Novotný et al. (2018), Sigma C0399 at 40 mg/kg i.p. modulated pulmonary vessel remodeling, confirming bioactivity in a second independent disease paradigm .

Ocular Allergy Prophylaxis Research and Formulation Development

In preclinical development of topical ophthalmic mast cell stabilizer formulations, cromolyn sodium salt ≥95% serves as the reference standard for benchmarking novel compounds. The clinical trial data of Katelaris et al. (2002) established that cromolyn sodium 2% ophthalmic solution QID produces significant within-group reductions in ocular itching and redness at 6 weeks, with approximately 20% reduction in itching at 30 minutes post-instillation [1]. Although dual-action agents such as olopatadine demonstrate superior efficacy at high pollen loads (5× lower symptom–pollen regression slope, P = 0.002), the well-characterized safety profile and pure mast cell stabilization mechanism of cromolyn sodium make it an essential comparator arm in dose-ranging and formulation optimization studies. The high water solubility facilitates preparation of preservative-free single-dose formulations for sensitive ocular surface models .

Analytical Method Development and Quality Control Reference Material

The ≥95% purity grade cromolyn sodium salt, combined with the published stability-indicating HPLC method of Barnes et al. (2002) featuring an LOQ of 0.05% for cromolyn and its two primary impurities, provides a cost-effective reference material for developing and validating in-house chromatographic methods [1]. The USP monograph establishes the pharmaceutical-grade acceptance criteria (98.0–101.0%), against which the research-grade material can be benchmarked. The forced degradation data confirming spectral peak purity and resolution from all detectable degradation products support the use of this product as a system suitability test material in HPLC method transfer and routine quality assessment of cromolyn-containing formulations [1]. This application scenario is particularly relevant for academic laboratories and CROs that require a characterized reference standard without the cost premium of USP-grade material.

FAQ

Q1: What is your regular lead time for sample and official order?

A1: Sample lead time 5-7 days. Official order lead time 14-21 days.

Q2: What is your MOQ?

A2: MOQ usually is 1kg.

Q3: How you control product quality?

A3: From raw material inspection, dupro inspection to final product inspection are executed strictly.

Q4: What is your warranty policy?

A4: We will send you a new batch if there is any quality issue during warranty time

Q5: Do you refund if customer receive defective product and do not accept replacement?

A5: Yes

Item Photo